Latest Insider Transactions at Day One Biopharmaceuticals, Inc. (DAWN)
This section provides a real-time view of insider transactions for Day One Biopharmaceuticals, Inc. (DAWN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Day One Biopharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Day One Biopharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 08
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,795
-0.14%
|
$35,900
$20.0 P/Share
|
|
Jul 05
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
800
-0.24%
|
$16,000
$20.0 P/Share
|
|
Jul 05
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
800
-0.17%
|
$16,000
$20.0 P/Share
|
|
Jul 05
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
857
-0.07%
|
$17,140
$20.0 P/Share
|
|
Jul 01
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
1,479
-0.44%
|
$29,580
$20.0 P/Share
|
|
Jul 01
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
1,000
-0.22%
|
$20,000
$20.0 P/Share
|
|
Jul 01
2022
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.25%
|
$190,000
$19.14 P/Share
|
|
Jul 01
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,746
-0.14%
|
$34,920
$20.0 P/Share
|
|
Jul 01
2022
|
Atlas Venture Opportunity Fund I, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
198,280
-20.0%
|
-
|
|
Jun 17
2022
|
Michael Gladstone |
BUY
Open market or private purchase
|
Indirect |
766,667
+50.0%
|
$11,500,005
$15.0 P/Share
|
|
Jun 17
2022
|
Atlas Venture Opportunity Fund Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
766,667
+50.0%
|
$11,500,005
$15.0 P/Share
|
|
Jun 17
2022
|
Ai Day1 LLC |
BUY
Open market or private purchase
|
Direct |
1,200,000
+10.1%
|
$18,000,000
$15.0 P/Share
|
|
Jun 15
2022
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
50,000
-3.66%
|
$800,000
$16.26 P/Share
|
|
Jan 20
2022
|
Ai Day1 LLC |
BUY
Open market or private purchase
|
Direct |
4,615
+0.05%
|
$64,610
$14.73 P/Share
|
|
Jan 19
2022
|
Ai Day1 LLC |
BUY
Open market or private purchase
|
Direct |
58,818
+0.62%
|
$823,452
$14.7 P/Share
|
|
Jan 18
2022
|
Ai Day1 LLC |
BUY
Open market or private purchase
|
Direct |
43,429
+0.46%
|
$608,006
$14.26 P/Share
|
|
Jan 03
2022
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.36%
|
$170,000
$17.18 P/Share
|
|
Dec 21
2021
|
Canaan Xi L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
536,000
-5.26%
|
-
|
|
Dec 08
2021
|
Canaan Xi L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
536,000
-4.99%
|
-
|
|
Dec 08
2021
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
110,338
-1.77%
|
$1,986,084
$18.03 P/Share
|
|
Dec 07
2021
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
186,935
-1.47%
|
$3,364,830
$18.97 P/Share
|
|
Dec 06
2021
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
97,692
-1.5%
|
$1,758,456
$18.05 P/Share
|
|
Dec 03
2021
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
12,517
-0.19%
|
$225,306
$18.47 P/Share
|
|
Dec 01
2021
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.24%
|
$170,000
$17.56 P/Share
|
|
Nov 24
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
801,138
-10.0%
|
-
|
|
Nov 24
2021
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
57,224
+0.87%
|
-
|
|
Oct 22
2021
|
Samuel C. Blackman HEAD OF R&D |
BUY
Bona fide gift
|
Indirect |
1,000,000
+50.0%
|
-
|
|
Oct 22
2021
|
Samuel C. Blackman HEAD OF R&D |
SELL
Bona fide gift
|
Direct |
1,000,000
-41.9%
|
-
|
|
Jun 01
2021
|
Ai Day1 LLC |
BUY
Open market or private purchase
|
Direct |
875,000
+8.53%
|
$14,000,000
$16.0 P/Share
|
|
Jun 01
2021
|
Ai Day1 LLC |
BUY
Conversion of derivative security
|
Direct |
8,502,776
+50.0%
|
-
|
|
Jun 01
2021
|
Canaan Xi L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
13,000
+0.12%
|
$208,000
$16.0 P/Share
|
|
Jun 01
2021
|
Canaan Xi L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
7,476,776
+21.15%
|
-
|
|
Jun 01
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
500,000
+50.0%
|
$8,000,000
$16.0 P/Share
|
|
Jun 01
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
8,502,776
+50.0%
|
-
|
|
Jun 01
2021
|
Papanek Julie Grant Director |
BUY
Open market or private purchase
|
Indirect |
13,000
+0.12%
|
$208,000
$16.0 P/Share
|
|
Jun 01
2021
|
Papanek Julie Grant Director |
BUY
Conversion of derivative security
|
Indirect |
7,476,776
+21.15%
|
-
|
|
Jun 01
2021
|
Daniel J. Becker Director |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$80,000
$16.0 P/Share
|
|
Jun 01
2021
|
John A. Josey |
BUY
Open market or private purchase
|
Direct |
7,000
+8.83%
|
$112,000
$16.0 P/Share
|